Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 1, 2026 · Other material event · Financial statements
CITIUS ONCOLOGY, INC.
8
Other material event
Jun 1, 2026
| ItemItem | Disclosure |
|---|---|
| Item 8.01 | Other events the company considers material |
| Item 9.01 | Financial statements and exhibits |
CITIUS ONCOLOGY, INC. filed this to release information to investors under Regulation FD — usually a press release, conference presentation, or other event the company considers important. htm PRESS RELEASE, DATED JUNE 1, 2026 Exhibit 99. 1 Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR ® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies Investigator-initiated study data presented May 30, 2026, at the American Society of Clinical Oncology…
This filing reports Item 8.01 (other events the company considers material). These item codes often precede or accompany restructuring, leadership changes, or deals that can shift headcount.
CITIUS ONCOLOGY, INC. reported material events that can affect workforce planning. cutoffs surfaces the filing alongside WARN layoffs, H-1B activity, and company signals.
